Mode
Text Size
Log in / Sign up
N/A Completed N=93

Study Evaluating the Safety of Enbrel (Etanercept)

Arthritis, Psoriatic
Source: ClinicalTrials.gov NCT00683384 ↗
Enrolled (actual)
93
Serious AEs
1.1%
Results posted
Nov 2010
Primary outcomePrimary: Number of Participants With Spontaneous Adverse Events Reported Until 30 Days After Each Injection — 7 Participants

Summary

The purpose of this study is to collect post-marketing information on the safety of Enbrel in Filipino patients.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Spontaneous Adverse Events Reported Until 30 Days After Each Injection
7 —

Eligibility Criteria

Inclusion Criteria

  • All patients from the study center who received or will receive at least one dose of Enbrel according to the approved product indication.

Exclusion Criteria

  • Previously discontinued Enbrel therapy due to significant safety concern.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00683384). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search